Drugs / Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Cell therapy targets WT1 via depletion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02408016 | May 2015 → Jun 2020 | malignant pleural mesothelioma, non-small cell lung carcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02408016 ↗ |
| Action | Deplete | “programmed to find cells with WT1 and kill them” NCT02408016 ↗ |
| Modality | Cell therapy | “genetically modified T cells” NCT02408016 ↗ |
| Route | Intravenous | “autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes intravenously (IV)” NCT02408016 ↗ |
| Target | WT1 | “programmed to find cells with WT1 and kill them” NCT02408016 ↗ |